Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Psychiatr. Apr 19, 2020; 10(4): 29-33
Published online Apr 19, 2020. doi: 10.5498/wjp.v10.i4.29
Published online Apr 19, 2020. doi: 10.5498/wjp.v10.i4.29
Evidence for using dextromethorphan-quinidine for the treatment of agitation in dementia
Rajesh R Tampi, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH 44106, United States
Rajesh R Tampi, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH 44195, United States
Pallavi Joshi, Department of Psychiatry and Behavioral Sciences, Northwell Health-Staten Island University Hospital, Staten Island, NY 10306, United States
Padmapriya Marpuri, Department of Psychiatry, Einstein Medical Center, Philadelphia, PA 19141, United States
Deena J Tampi, Diamond Healthcare, Richmond, VA 23219, United States
Author contributions: All authors equally contributed to this manuscript.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Rajesh R Tampi, MD, Chairman, Department of Psychiatry and Behavioral Sciences, Cleveland Clinic Akron General, Akron, OH 44106, United States. rajesh.tampi@yale.edu
Received: February 8, 2020
Peer-review started: February 8, 2020
First decision: February 17, 2020
Revised: March 3, 2020
Accepted: March 22, 2020
Article in press: March 22, 2020
Published online: April 19, 2020
Peer-review started: February 8, 2020
First decision: February 17, 2020
Revised: March 3, 2020
Accepted: March 22, 2020
Article in press: March 22, 2020
Published online: April 19, 2020
Core Tip
Core tip: Dextromethorphan-quinidine is approved for the treatment of pseudobulbar affect and may be effective in managing agitation in dementia. There is only one published trial that has evaluated the use dextromethorphan-quinidine for agitation in dementia. The study was of good quality and found that dextromethorphan-quinidine decreases severity of agitation when compared to placebo. Additionally, dextromethorphan-quinidine was fairly well tolerated and did not appear to cause significant sedation or worsen cognitive symptoms among individuals with dementia.